Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Senior Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
COVID trial
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
23/11/2022
Nykode Therapeutics reports 3Q 2022 Financial Results
16/11/2022
Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022
07/11/2022
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
07/11/2022
Nykode Therapeutics to present at two upcoming investor conferences in November
28/10/2022
Nykode Therapeutics to Present a Poster on Interim Results from the Pre-planned Interim Analysis from the C-02 trial with VB10.16 in advanced cervical patients at the European Society of Gynaecological Oncology’s 23rd Annual Meeting (ESGO 2022)
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
